Lexicon Pharmaceuticals (LXRX) Other Gross PP&E Adjustments (2023 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed Other Gross PP&E Adjustments for 4 consecutive years, with -$6.8 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 49.07% to -$6.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.8 million, a 49.07% decrease, with the full-year FY2025 number at -$6.8 million, down 49.07% from a year prior.
- Other Gross PP&E Adjustments was -$6.8 million for Q4 2025 at Lexicon Pharmaceuticals, up from -$7.5 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$4.5 million in Q2 2025 to a low of -$7.5 million in Q3 2025.
- A 3-year average of -$5.5 million and a median of -$5.3 million in 2024 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: increased 22.74% in 2024, then crashed 49.67% in 2025.
- Lexicon Pharmaceuticals' Other Gross PP&E Adjustments stood at -$5.9 million in 2023, then rose by 22.74% to -$4.6 million in 2024, then crashed by 49.07% to -$6.8 million in 2025.
- Per Business Quant, the three most recent readings for LXRX's Other Gross PP&E Adjustments are -$6.8 million (Q4 2025), -$7.5 million (Q3 2025), and -$4.5 million (Q2 2025).